NLM Digital Collections

Search

Start Over Formats Text ✖Remove constraint Formats: Text Subjects Rare Diseases -- drug therapy ✖Remove constraint Subjects: Rare Diseases -- drug therapy

2. Slowly progressive, low-prevalence rare diseases with substrate deposition that result from single enzyme defects: providing evidence of effectiveness for replacement or corrective therapies

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, March 2020
Subject(s):
Drug Development -- standards
Drugs, Investigational
Rare Diseases -- drug therapy
Metabolism, Inborn Errors -- drug therapy
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.